Tamar Bar Ziv
A5095042691- Protein Kinase Regulation and GTPase Signaling
- PI3K/AKT/mTOR signaling in cancer
- Cancer therapeutics and mechanisms
- ATP Synthase and ATPases Research
- Receptor Mechanisms and Signaling
- Melanoma and MAPK Pathways
Revolution Medicines (United States)
2023-2024
Technion – Israel Institute of Technology
2024
Abstract RAS oncogenes (collectively NRAS , HRAS and especially KRAS ) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 61 1 . Small molecule inhibitors of KRAS(G12C) oncoprotein have demonstrated clinical efficacy patients multiple cancer types led to regulatory approvals for treatment non-small cell lung 2,3 Nevertheless, G12C account only around 15% -mutated cancers 4,5 there no approved majority tumours containing other...
Abstract Background Although GqPCR activation often leads to cell survival by activating the PI3K/AKT pathway, it was previously shown that in several types AKT activity is reduced and JNK apoptosis. The mechanism of inactivation these cells involves an IGBP1-coupled PP2Ac switch induces dephosphorylation both PI3K AKT. However, machinery involved initiation PP2A not known. Methods We used phospho-mass spectrometry identify phosphorylation site PP2Ac, raised specific antibodies follow...
Abstract RAS oncogenes (collectively NRAS , HRAS and especially KRAS ) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 61 1 . Small molecule inhibitors of G12C oncoprotein have demonstrated clinical efficacy patients multiple cancer types led to regulatory approvals for treatment non-small-cell lung (NSCLC) 2,3 Nevertheless, account only ~14% cancers 4 there no approved majority tumors harboring other mutations. Here, we describe...